Deprixol

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Deprixol

Property Description
Active Ingredient Venlafaxine (Venlafaxine hydrochloride)
Form Oral formulation (Immediate-release tablet, Extended-release capsule)
Pharmacological Class Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Common Use Treatment of mood and anxiety disorders
Origin Synthetic compound

What is Deprixol and What Type of Drug is it?

Deprixol is a specific prescription-only medicine formulation whose active substance is the internationally recognized drug Venlafaxine (Venlafaxine hydrochloride). It is officially classified as a Serotonin-Norepinephrine Reuptake Inhibitor (SNRI), a key category of psychotropic agents used to modulate the Central Nervous System (CNS). Venlafaxine is clinically recognized for its unique dual pharmacological action. This classification establishes the medicine's role as an antidepressant and anxiety treatment.

Composition, Form, and Origin

The core chemical entity, Venlafaxine, is a synthetic compound derived from phenethylamine and a cyclohexanol derivative, ensuring a defined chemical structure distinct from older medication classes. Deprixol is supplied as a single product in an oral formulation, intended for ingestion and systemic absorption. The medication is offered in two principal drug forms: an immediate-release tablet and an extended-release capsule (sustained-release). The extended-release capsule is specifically designed to maintain consistent drug levels throughout the day. This sustained profile helps support the continuous influence on the targeted neurochemical pathways.

General Purpose of Serotonin-Norepinephrine Reuptake Inhibitors

The general therapeutic purpose of Deprixol is to support the brain’s ability to regulate mood and emotional states in adults. As an SNRI, the drug’s primary action is to enhance the availability of the neurotransmitters serotonin and norepinephrine within the synapses, a process central to its monoamine potentiation. This supports the stabilization of emotional equilibrium and helps manage conditions characterized by dysregulation in these neurochemical pathways.

Regulatory References

  1. MedlinePlus: Venlafaxine Summary

What side effects are possible with Deprixol?

Possible Side Effects and Safety Information: Deprixol

Deprixol (Venlafaxine) is associated with an official safety profile categorized by frequency and the body systems affected, as documented in governmental regulatory sources. Adverse reactions are classified across several System-Organ Classes, including the Nervous System, Gastrointestinal System, Vascular System, and Psychiatric Disorders.


Frequency-Classified Adverse Reactions

The following are examples of adverse reactions grouped by their documented incidence:

  • Very Common (Affecting 1 in 10 or more people): Nausea, Dry mouth, Headache, Insomnia, and increased Sweating (Hyperhidrosis).
  • Common (Affecting 1 to 10 in 100 people): Dizziness, Somnolence (sleepiness), Constipation, Hypertension (raised blood pressure), Hot flush, and various sexual dysfunctions (e.g., decreased libido, erectile dysfunction).

Serious Adverse Reactions and Safety Constraints

Official labeling highlights the potential for Serious Adverse Reactions (SARs). A primary concern documented in the boxed warnings is the risk of Suicidal thoughts and behaviors, particularly in children, adolescents, and young adults. Other SARs include Serotonin Syndrome, a potentially life-threatening condition, and the risk of developing sustained Hypertension or certain Cardiac Arrhythmias.

Safety constraints note that the medicine is contraindicated in patients using MAOIs (Monoamine Oxidase Inhibitors). Furthermore, risks are specified for certain groups: Pediatric use is not approved. Patients with Hepatic or Renal impairment may require special consideration.

Exposure-related patterns also exist, with the risk of Suicidal thoughts being noted as higher during the first few months of treatment or upon dose change. Abrupt cessation may lead to Discontinuation Syndrome symptoms, as stated in regulatory documents.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Deprixol (Venlafaxine)

The following information is derived strictly from authoritative government regulatory documents.

Overdose Scope

Category Official Regulatory Statements
Documented overdose presentations Changes in level of consciousness (ranging from Somnolence to Coma), Drowsiness, Agitation, Seizures, Tachycardia, Mydriasis, Nausea, and Vomiting.
Physiological systems affected Central Nervous System (CNS), Cardiovascular (e.g., QRS/QT prolongation, Irregular heartbeat), and Musculoskeletal (e.g., Rhabdomyolysis).
Exposure-related factors Overdose has occurred predominantly in combination with alcohol and/or other medicinal products. Delayed onset of symptoms is possible with the extended-release (XR) formulation.
Emergency-response statements Management must be symptomatic and supportive, as no specific antidote is known. Measures include continuous cardiac monitoring and use of activated charcoal.
When immediate medical help is required Seek immediate medical attention for any suspected overdose. Immediately call emergency services (e.g., 911) if the person has collapsed, had a seizure, has trouble breathing, or cannot be awakened. Prompt contact with a poison control center is advised.

Overdose Classifications (High-Level)

Category Official Regulatory Statements
Severity classification Overdose is associated with a risk of life-threatening outcomes, including Serotonin Syndrome and Death.
Overdose-context constraints Close observation and continuous cardiac monitoring are required due to the potential for serious complications and the delayed absorption of the XR formulation.

Resulting Overdose Structure

Official overdose statements:

  • Documented serious outcomes include Serotonin Syndrome, QRS and QT prolongation, Ventricular dysrhythmias (e.g., Torsades de pointes), and Rhabdomyolysis.
  • No specific antidote is known for Venlafaxine, requiring management to be purely symptomatic and supportive.
  • Immediate medical attention is required for any suspected overdose due to the potential for life-threatening manifestations.

Connection to the overall overdose profile: Regulatory documents define the overdose profile by the risk of severe CNS and cardiovascular toxicity, specifically noting the potential for Serotonin Syndrome and significant ECG abnormalities. This necessitates the clear regulatory mandate to seek immediate medical attention and establish continuous cardiac monitoring and supportive care, particularly because no specific antidote is known and symptoms may be delayed with the extended-release formulation.

Therapeutic Uses of Deprixol

Deprixol (Venlafaxine) is commonly used across conditions presenting with acute episodes, primarily addressing the emotional, psychological, and symptoms related to physical discomfort of mood and anxiety disorders. It is relevant for managing symptom distress in Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Social Anxiety Disorder, and Panic Disorder. It provides support that generally assists with managing symptomatic distress and supports patients during episodes of heightened discomfort.


Easing Core Symptoms and Supporting Stability

This medication is applied in clinical settings that involve acute or unstable symptom patterns, helping to ease the symptom burden of profound low mood, anhedonia, chronic worry, and disruptive panic attacks. The medication may assist with easing the symptom of anhedonia, which is the symptom of loss of pleasure, and supports general well-being. It is also applied in scenarios where supportive relief is needed to manage associated physical symptoms like fatigue and vasomotor symptoms (hot flashes).

“It is commonly used to help with symptoms that interfere with daily comfort and are linked to heightened emotional and physical tension.”

Quick Fact: Support for Functional Strain Deprixol is considered relevant for easing symptoms that create noticeable functional strain, assists with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus overview on Venlafaxine

Eligibility and Restrictions for Use

Who Can and Cannot Use Deprixol?

Eligibility for Deprixol (Venlafaxine) is determined by official regulatory documents based on age, physiological status, and co-existing medical conditions. The medicine is not approved for standard use in all populations.


Eligibility Status by Population

Population Group Regulatory Status
Adults (18 years and older) Approved for use under standard labeled conditions.
Children / Adolescents (< 18 years) Not recommended; not FDA-approved for pediatric patients.
Older Adults (Geriatric) Use is established, but caution is advised due to potential sensitivity and reduced renal function.

Absolute Prohibitions (Contraindications)

Deprixol is contraindicated and must not be used in patients with a known hypersensitivity to venlafaxine or any component of the formulation. Use is strictly prohibited concurrently with Monoamine Oxidase Inhibitors (MAOIs), or within 14 days of stopping an irreversible MAOI.


Conditions Requiring Restriction

Eligibility is restricted for patients with hepatic (liver) or renal (kidney) impairment, requiring a mandatory dose reduction as defined by regulatory bodies. Conditional use and caution are also required for patients with a history of seizures, uncontrolled hypertension, Bipolar Disorder, or Angle-Closure Glaucoma risk. For pregnancy and lactation, use is conditional; the label advises weighing the drug's importance against the potential risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Deprixol (Venlafaxine) has officially documented interaction patterns that are classified based on the resulting impact on the body, as outlined in government regulatory labels.


Pharmacodynamic and Contraindicated Interactions

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is contraindicated, including products like linezolid and intravenous methylene blue, due to the formal risk of Serotonin Syndrome. A mandatory washout period is required when switching between these agents. Other serotonergic drugs, such as SSRIs, triptans, or fentanyl, also involve a documented pharmacodynamic interaction that increases this risk. Furthermore, combining Deprixol with CNS-acting drugs may result in an additive impairment of cognitive or motor skills, and co-administration with hemostatic agents (e.g., NSAIDs, warfarin) increases the formal risk of bleeding.

Pharmacokinetic and Substance Interactions

Interactions involving metabolism are officially noted. Co-administration with CYP2D6 inhibitors or CYP3A4 inhibitors (e.g., ketoconazole) may increase the plasma concentration of venlafaxine or its active metabolite, O-desmethylvenlafaxine. Conversely, CYP3A4 inducers (e.g., rifampin) may reduce exposure. The official label also advises avoiding or limiting the use of alcohol due to documented additive impairment and warns of the pharmacodynamic interaction risk posed by the herbal product St. John’s Wort.

Mechanism of Action

Dual Inhibition of Key Neurotransmitter Transporters

Deprixol acts at the molecular level by selectively inhibiting the reuptake of two primary neurotransmitters: serotonin and norepinephrine. This action prevents the Serotonin Transporter ( SERT) and the Norepinephrine Transporter ( NET) from rapidly clearing these molecules from the synaptic cleft, resulting in their immediate and sustained increase in concentration. This dual-action increases the functional availability of signaling molecules within the Central Nervous System (CNS) and initiates the molecular cascade necessary for the drug’s physiological effects.


Neuroplastic Adaptation and Pathway Modulation

The persistent increase in monoamine levels triggers a neuroplastic adaptation in the receiving neurons, leading to long-term changes in receptor sensitivity and overall cellular response. This cascade of events, which takes time to develop, is the primary mechanism through which the drug modulates the physiological signaling of CNS regions involved in complex behavioral and cognitive processing. The same mechanism also results in potentiation of descending pain inhibitory pathways, which modulates afferent sensory input.


Concentration-Dependent Mechanistic Shift

The dual inhibitory mechanism of Deprixol is not uniform across all physiological concentrations. Its primary action at lower concentrations is focused on serotonin reuptake, while the inhibition of norepinephrine reuptake becomes fully engaged only as the concentration increases. This intrinsic concentration-dependent mechanistic shift results in the modulation of both serotonergic and noradrenergic systems.

Dosage and Administration Information

The use of Deprixol, which contains Venlafaxine, is restricted to the oral route of administration. Administration differs based on the formulation: the extended-release (ER) form is taken once daily, while the immediate-release (IR) tablet requires administration in divided doses across the day. Both formulations are taken with food to support consistent absorption.


The standard administration follows a defined titration schedule. For the extended-release form, treatment typically begins at 75 mg once daily, though a lower initial dose may be used for a short period. Dosage adjustments, if required, are made in increments of up to 75 mg and separated by an interval of not less than four days to reach the target maintenance dose. The maximum dose for general outpatient use is 225 mg daily for the ER formulation.


Patients using the extended-release forms must swallow the tablet or capsule whole; the medication must not be crushed, divided, or chewed, as this compromises its slow-release design. Dose modification is applicable for specific patient groups: a substantial reduction (e.g., 25% to 50% or more) is indicated for individuals with documented renal or hepatic impairment. Furthermore, discontinuation is managed by a gradual dose reduction (tapering) over a period of at least one to two weeks.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Deprixol (Venlafaxine)

1. Evidence for use in Major Depressive Disorder (MDD)

Research for Deprixol (Venlafaxine) in the context of Major Depressive Disorder (MDD) has been explored primarily through controlled studies. Researchers utilized multiple short-term (typically 4- to 12-week) Randomized Controlled Trials (RCTs). Outcomes related to symptom intensity were monitored using standardized rating scales. Studies monitored how outcomes related to depressive symptoms (such as low mood and anhedonia) and functional status were measured across the acute study period. Research also explored whether these measurements were sustained by conducting longer-term maintenance studies, typically lasting up to 26 weeks.

2. Evidence for use in Generalized Anxiety Disorder (GAD)

Deprixol was evaluated in studies for Generalized Anxiety Disorder (GAD), which is a condition marked by functional limitations. The core research consisted of short-term (8-week) RCTs, designed to explore how symptoms change over time and to assess patient-reported outcomes describing perceived discomfort. Findings describe patterns observed in the studies related to changes in anxiety scale scores over the 8-week period. The research describes differences in the rates of relapse during the long-term maintenance phase between the groups randomly assigned to Deprixol and the comparison group.

3. Evidence for use in Social Anxiety Disorder (SAD) and Panic Disorder (PD)

Research examined the use of Deprixol for both Social Anxiety Disorder (SAD) and Panic Disorder (PD). For SAD, research explored short-term symptom changes, often over a 12-week period, using RCTs designed to evaluate outcomes reflecting daily functioning. For Panic Disorder, studies monitored episodic or acute changes and examined outcomes capturing phases of heightened symptom activity.

4. What is Still Uncertain About the Research for Deprixol

A significant limitation is that follow-up durations were limited in many acute studies, and long-term effects are not fully established for periods beyond the structured maintenance trials. While research examined adult populations, data for certain groups remain insufficient, as studies in pediatric populations reported mixed findings. Research also examined other contexts, such as vasomotor symptoms, which has been evaluated in RCTs, resulting in a moderate evidence level; however, the data lacks regulatory consensus from major health authorities.

Frequently Asked Questions (FAQ)

Common questions about Deprixol (FAQ)

Q: What are the most common side effects people report when starting Deprixol?

Official documents list common adverse reactions during treatment, which include feeling sick (nausea), dry mouth, headache, and trouble sleeping (insomnia).

Regulatory warnings indicate that the risk of suicidal thoughts and behaviors is highest during the initial few months of therapy or whenever the dosage is changed.


Q: What are the main things to avoid while taking Deprixol?

Official documentation advises against using the medicine concurrently with MAOIs (a class of antidepressants) and suggests limiting or avoiding alcohol use.

Patients taking the extended-release form are advised not to crush or chew the capsules. Regulatory warnings note that activities like driving or operating heavy machinery may be impaired until the individual understands how the medicine affects them, as it may cause drowsiness.


Q: What is the typical time frame before the full expected effect of Deprixol is noticed?

The drug's mechanism involves neuroplastic adaptation (changes in nerve signaling) in the brain, which is a process that takes time to develop.

The clinical trials used to establish effectiveness typically assess changes in symptoms over a period of 8 to 12 weeks.


Q: How is Deprixol different from other similar medicines in its class?

Deprixol is classified as a Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) because it works by blocking the reuptake of two key brain chemicals: serotonin and norepinephrine.

Official documents describe that its effect is concentration-dependent: at lower concentrations, the effect is mainly on serotonin, but the inhibition of norepinephrine becomes more significant at higher concentrations.


Q: What is the purpose of the different strengths or dosages Deprixol comes in?

Official guidelines describe starting treatment at a lower dose and gradually increasing the dose over time (titration).

The process is described as a strategy to modulate the drug's effects over time while allowing for individual adjustment. Regulatory documents indicate that the drug's effect on norepinephrine reuptake becomes fully engaged as the dose increases.


Q: Why is Deprixol sometimes described as having a specific effect on certain brain chemicals?

Deprixol is described this way because it officially works by blocking the reuptake of two specific neurotransmitters (serotonin and norepinephrine) in the brain.

This action increases the functional availability of these signaling molecules, which is the mechanism necessary for the drug’s effects on mood and emotional regulation.


Q: Is it safe to switch from a similar medicine to Deprixol?

The regulatory guidelines discuss that when stopping one drug to start another, a process of gradual dose reduction (tapering) of the former medicine may be required to minimize discontinuation effects.

Regulatory guidelines strictly prohibit the use of Deprixol at the same time as MAOIs (Monoamine Oxidase Inhibitors) and mandate a washout period when switching from these agents.


Q: What is still uncertain about the research for Deprixol?

Research summaries indicate that long-term effects are not fully established for treatment periods extending beyond the structured maintenance trials.

Furthermore, official data for certain patient groups remains insufficient, and studies conducted in pediatric populations (children and adolescents) have reported mixed findings.


Q: Is it normal to feel a bit sleepy after taking Deprixol?

Yes, feeling sleepy (somnolence) is listed in official documents as a common adverse reaction.

This means that this effect is expected to occur in 1 to 10 out of every 100 people using the medication.


Q: Can Deprixol be taken with pain relievers like ibuprofen?

Regulatory information states that using this medicine with NSAIDs (a class of pain reliever that includes ibuprofen) may increase the formal risk of bleeding events.

The regulatory information indicates this combination carries a formal risk of bleeding events.


Q: Are there any specific vitamins or supplements that are known to interact with Deprixol?

Official documents specifically warn against using the herbal product St. John’s Wort due to the risk of interaction.

For other vitamins and supplements, a general lack of controlled research data means the effects of combining them with this medicine are not fully established in regulatory documents.


Q: Is it true that Deprixol can affect the heart rhythm?

Official warnings highlight the potential for Cardiac Arrhythmias (irregular heart rhythm) as a serious adverse reaction.

The official warnings highlight the potential for Cardiac Arrhythmias (irregular heart rhythm) as a serious adverse reaction.


Q: Does Deprixol require special monitoring or blood tests?

Regulatory labeling advises that blood pressure should be checked regularly throughout treatment.

Additional monitoring for certain conditions, such as the potential for low sodium levels (hyponatremia) and eye pressure in patients at risk of glaucoma, may also be advised in official documents.


Q: Does Deprixol cause feelings of anxiety or nervousness?

Official documents list nervousness and anxiety as documented side effects of the medicine.


Q: Why do some people experience initial side effects that fade over time?

Patient information derived from official sources notes that some common adverse effects may gradually lessen as the body adjusts to the medicine.

This adjustment is consistent with the initial changes described in the official documents for the medicine.


Q: Is there any research that looks at how long the effects of Deprixol last after stopping?

Official documents primarily discuss the risk of developing Discontinuation Syndrome symptoms if the medicine is stopped abruptly without a gradual reduction (tapering).

These temporary symptoms often begin within a few days of dose reduction.


Q: What should be done if a person accidentally takes too much Deprixol?

Official regulatory documents state that an overdose of this medicine can be life-threatening.

Regulatory documents indicate that seeking immediate emergency medical attention and contacting a poison control center is necessary if an overdose is suspected.


Q: Is it possible for Deprixol to make certain conditions feel worse initially?

Regulatory warnings advise monitoring for any indication of clinical worsening of the condition being treated, as well as the emergence of suicidal thoughts and behaviors.

This monitoring is particularly important during the initial few months of therapy or upon any dose change.


Q: Are there any long-term effects associated with using Deprixol for many years?

Research summaries indicate that long-term effects are not fully established beyond the structured maintenance trials.

However, regulatory sources note that some side effects, such as sexual dysfunction, may in rare cases persist after discontinuation.


Q: Can Deprixol affect sleep patterns?

Official documents list several common effects on sleep patterns, including insomnia (trouble sleeping) and somnolence (drowsiness).

Additionally, the occurrence of abnormal dreams is also listed as a documented adverse reaction.


Q: Does the time of day a person takes Deprixol matter?

For the extended-release form, official guidelines state that the medicine can be taken as a single daily dose with food.

It can be taken either in the morning or in the evening, but should be taken at approximately the same time each day, as stated in the official guidelines.


Q: Is Deprixol known to interact with birth control pills?

Official drug interaction sections do not list any established interaction between Deprixol (Venlafaxine) and oral contraceptives (birth control pills).

This means no known contraindications have been identified in regulatory documents.


Q: Is it possible to experience a lack of effect from Deprixol?

Regulatory documents confirm that not all patients may respond adequately to the initial dose.

Prescribing information allows for dose increases in patients who are not responding to the starting dose to seek a better effect, up to the maximum recommended dose.


Q: Does Deprixol cause skin sensitivity to the sun?

Regulatory sources describe photosensitivity reactions as a documented, uncommon adverse reaction.

Patients who experience this may have an increased risk of reactions, such as severe sunburn, on sun-exposed skin.


Q: Are there any known interactions between Deprixol and common psychiatric medicines?

Regulatory documents specifically warn of a potential pharmacodynamic interaction with other serotonergic drugs (a class that includes many psychiatric medicines and triptans).

This is due to the formal risk of a serious condition called Serotonin Syndrome. Co-administration with MAOIs is strictly prohibited.


Q: Is Deprixol used to treat pain?

While the drug is primarily approved for the treatment of mood and anxiety disorders, the medicine's mechanism of action is described in official documentation as also resulting in the potentiation of descending pain inhibitory pathways.

How should Deprixol be stored and disposed of?

How to Store and Dispose of Deprixol (Venlafaxine)

Official regulatory guidelines define precise conditions for storing and discarding Deprixol oral formulations to ensure product integrity and safety.

️ Storage Requirements

Condition Requirement (Official Labeling)
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F), avoiding excessive heat.
Container Keep the medicine in its original container, tightly closed. Extended-release capsules must remain in the original bottle.
Protection Protect from moisture; do not store the medication in the bathroom.
Child Safety Mandatory to keep this medication out of the sight and reach of children.

️ Disposal Instructions

Unused or expired medication should be taken to a community drug take-back program for proper disposal. If a program is unavailable, the medication should be mixed with an undesirable substance (e.g., used coffee grounds) and placed in a sealed bag before being thrown into the household trash. Deprixol is not recommended for disposal by flushing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Deprixol found in:

A-Z Index: